|, Mavorixafor in Waldenstrom Macroglobulinemia, CXCR4 in Primary Immunodeficiency Diseases. Only 24.43% of the stock of CarGurus is held by insiders. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of X4 Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. Visit a quote page and your recently viewed tickers will be displayed here. Create a list of the investments you want to track. The Boston-based company said it had a … 5 brokers have issued 12 month price targets for Allena Pharmaceuticals' stock. 79.44% of the stock of CarGurus is held by institutions. Dollar up 0.1% versus Japanese currency at 108.57 yen, The stimulus money isn’t going to be spent, Bank of America says, so here are the investment moves to make, Dollar weakens versus major rivals after CPI data, GE CEO: 'Momentum is building' across the co., and now 'shifting more to offense', Just Eat Takeaway Losses Widen as Battle With Deliveroo and Uber Eats Intensifies, Vera Bradley reports Q4 earnings that beat expectations but 2021 could fall short, Talend agrees to be acquired by Thoma Bravo in $2.4 bln deal, X4 Pharmaceuticals started at buy with $27 stock price target at Stifel Nicolaus, U.S. consumer prices rose 0.4% in February; 12-month inflation rate hits 1.7%, X4 Pharmaceuticals (XFOR) Received its Third Buy in a Row, Oppenheimer Assigns a Buy Rating on X4 Pharmaceuticals (XFOR), X4 Pharmaceuticals (XFOR) Gets a Buy Rating from Brookline Capital Markets, X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher, B.Riley Financial Reiterates Their Buy Rating on X4 Pharmaceuticals (XFOR), Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (XFOR), Regeneron (REGN) and Zimmer Biomet Holdings (ZBH), Oppenheimer Thinks X4 Pharmaceuticals’ Stock is Going to Recover, Arsanis Inc (XFOR) Moves to Buy: Rationale Behind the Upgrade. This suggests a possible upside of 607.5% from the stock's current price. ALNY | Complete Alnylam Pharmaceuticals Inc. stock news by MarketWatch. © 2021 X4 Pharmaceuticals, Inc. All rights reserved. Aberrant functioning of CXCR4 is associated with certain PI diseases. Their average twelve-month price target is $41.46, predicting that the stock has a possible downside of 20.05%. Specifically, they have bought $22,140.00 in company stock and sold $0.00 in company stock. X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website. X4 Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy. X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020... February 11, 2021 Analysts expect X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) to announce earnings of ($0.87) per share for the current fiscal quarter, according to Zacks. X4 Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Mit über 20 Jahren Erfahrung haben wir einen Broker entwickelt, der auf die Bedürfnisse der Anleger zugeschnitten ist. Earnings and Valuation of Palatin Technologies (NYSEAMERICAN:PTN View real-time stock prices and stock quotes for a full financial overview. X4 Pharmaceuticals to Announce Fourth Quarter and Full Year... X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website. CRSR has a C grade for Quality also. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. March 04, 2021 Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 141.68%. X4 is developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers, such as lymphomas. Intraday Data provided by FACTSET and subject to terms of use. The consensus rating is ‘Buy’. BOSTON (AP) _ X4 Pharmaceuticals, Inc. (XFOR) on Thursday reported a loss of $18.4 million in its fourth quarter. The range between the high target price and low target price is between 23 and 14 calculating the mean target price we have 18.75. Our grit drives solutions for patients. View real-time stock prices and stock quotes for a full financial overview. Find the latest Kiniksa Pharmaceuticals, Ltd. (KNSA) stock quote, history, news and other vital information to help you with your stock trading and investing. On average, they expect Allena Pharmaceuticals' stock price to reach $10.40 in the next year. Celcuity (CELC)traded 7.8% down premarketafter pricing its now upsized underwritten public offering (earlier $20M in shares) of 1.71M shares at $14/share. Intraday data delayed at least 15 minutes or per exchange requirements. X4 Pharmaceuticals with ticker code (XFOR) now have 8 analysts in total covering the stock. Log in to see them here or sign up to get started. Volatility & Risk. Copyright © 2021 MarketWatch, Inc. All rights reserved. In the past three months, CarGurus insiders have sold more of their company’s stock than they have bought. By targeting the CXCR4 pathway, our novel medicines are designed to restore healthy immunity in patients with rare diseases. The high price target for NVTA is $64.00 and the low price target for NVTA is … BOSTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel … This browser is no longer supported at MarketWatch. Continue Subscriber Agreement & Terms of Use, Have Watchlists? By using this site you agree to the X4 has initiated a phase 3 clinical trial for lead candidate, Mavorixafor, for the PI disease, WHIM Syndrome. There are currently no items in this Watchlist. Privacy Notice, and Zero analysts have provided estimates for X4 Pharmaceuticals’ earnings, with estimates ranging from ($0.97) to ($0.74). Something went wrong while loading Watchlist. Über uns Mit wallstreet:online, ariva.de, FinanzNachrichten.de und börsenNEWS.de sind wir Marktführer im Bereich Finanzinformationen. Comparatively, INmune Bio has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Every day, we strive to advance our pipeline of innovative medicines to treat rare diseases. XFOR | Complete X4 Pharmaceuticals Inc. stock news by MarketWatch. This is justified given that the stock retreated 7.5% over the past month and gained 0.3% year-to-date. X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment … 7 Wall Street analysts have issued ratings and price targets for Invitae in the last 12 months. Specifically, they have bought $0.00 in company stock and sold $5,037,174.00 in company stock. Their forecasts range from $5.00 to $18.00. For the best MarketWatch.com experience, please update to a modern browser. "Communities face multiple competing crises in addition to COVID, and leaders are exhausted with planning fatigue," said Christine Bechtel, co-founder, X4 Health. Analyst Opinion on Kala Pharmaceuticals (NASDAQ:KALA) 7 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. BiondVax Pharmaceuticals' stock was trading at $6.5350 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Only 6.20% of the stock of Palatin Technologies is held by insiders. X4 Pharmaceuticals reported earnings per share of ($0.66) in the same quarter last year, which suggests … Only 11.74% of the stock of Palatin Technologies is held by institutions. Cookie Notice (). Since then, BVXV stock has decreased by 44.6% and is now trading at $3.62.